FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2084295556> ?p ?o ?g. }

• W2084295556 endingPage "1226" @default.
• W2084295556 startingPage "1221" @default.
• W2084295556 abstract "Objectives To evaluate estrogen receptors as a therapeutic target for human bladder cancer. Methods The ability of the selective estrogen receptor modulators (SERMs) tamoxifen and raloxifene to inhibit 5637 human transitional cell carcinoma cell proliferation was determined in vitro and in xenograft studies using 5637 cells in female athymic BALB/c nu/nu mice. Results Treatment with tamoxifen, raloxifene, or the pure antiestrogen ICI 182,780 inhibited proliferation of 5637 cells in vitro. In the first xenograft study, raloxifene (10, 100, or 1000 μg/day) administered by oral gavage inhibited the growth of tumors compared with placebo or untreated controls (P <0.05). In a second experiment, tamoxifen (8.3, 125, or 1250 μg/day) delivered by time-release pellet inhibited tumor growth compared with placebo-treated controls (P <0.01). A comparison study in which tamoxifen (8.3 or 125 μg/day) or raloxifene (100 μg/day) was administered by slow-release pellet demonstrated that both SERMs reduced growth compared to placebo-treated controls (P <0.05), with comparable effectiveness. There was no detectable tumor in 17 of 30 treated mice. In all studies, average tumor volumes in SERM-treated animals declined over the course of treatment. Conclusions Selective estrogen receptor modulators inhibit the growth of 5637 transitional cell carcinoma cell xenografts, supporting the rationale to evaluate these agents as targeted therapeutics for patients with urothelial carcinoma. To evaluate estrogen receptors as a therapeutic target for human bladder cancer. The ability of the selective estrogen receptor modulators (SERMs) tamoxifen and raloxifene to inhibit 5637 human transitional cell carcinoma cell proliferation was determined in vitro and in xenograft studies using 5637 cells in female athymic BALB/c nu/nu mice. Treatment with tamoxifen, raloxifene, or the pure antiestrogen ICI 182,780 inhibited proliferation of 5637 cells in vitro. In the first xenograft study, raloxifene (10, 100, or 1000 μg/day) administered by oral gavage inhibited the growth of tumors compared with placebo or untreated controls (P <0.05). In a second experiment, tamoxifen (8.3, 125, or 1250 μg/day) delivered by time-release pellet inhibited tumor growth compared with placebo-treated controls (P <0.01). A comparison study in which tamoxifen (8.3 or 125 μg/day) or raloxifene (100 μg/day) was administered by slow-release pellet demonstrated that both SERMs reduced growth compared to placebo-treated controls (P <0.05), with comparable effectiveness. There was no detectable tumor in 17 of 30 treated mice. In all studies, average tumor volumes in SERM-treated animals declined over the course of treatment. Selective estrogen receptor modulators inhibit the growth of 5637 transitional cell carcinoma cell xenografts, supporting the rationale to evaluate these agents as targeted therapeutics for patients with urothelial carcinoma." @default.
• W2084295556 created "2016-06-24" @default.
• W2084295556 creator A5014262615 @default.
• W2084295556 creator A5014453742 @default.
• W2084295556 creator A5023436882 @default.
• W2084295556 creator A5036761918 @default.
• W2084295556 creator A5047315296 @default.
• W2084295556 creator A5048604566 @default.
• W2084295556 creator A5052069729 @default.
• W2084295556 creator A5056602302 @default.
• W2084295556 creator A5081834953 @default.
• W2084295556 date "2007-06-01" @default.
• W2084295556 modified "2023-09-25" @default.
• W2084295556 title "Efficacy of Selective Estrogen Receptor Modulators in Nude Mice Bearing Human Transitional Cell Carcinoma" @default.
• W2084295556 cites W1807939285 @default.
• W2084295556 cites W1961026612 @default.
• W2084295556 cites W1988066591 @default.
• W2084295556 cites W1993648017 @default.
• W2084295556 cites W2000361608 @default.
• W2084295556 cites W2014580625 @default.
• W2084295556 cites W2018546973 @default.
• W2084295556 cites W2022615979 @default.
• W2084295556 cites W2031846517 @default.
• W2084295556 cites W2047565556 @default.
• W2084295556 cites W2057861156 @default.
• W2084295556 cites W2064718266 @default.
• W2084295556 cites W2068794826 @default.
• W2084295556 cites W2107308295 @default.
• W2084295556 cites W2112629831 @default.
• W2084295556 cites W2116654760 @default.
• W2084295556 cites W2126298326 @default.
• W2084295556 cites W2146750091 @default.
• W2084295556 cites W2151307577 @default.
• W2084295556 cites W2155274896 @default.
• W2084295556 cites W2155444885 @default.
• W2084295556 cites W2155824843 @default.
• W2084295556 cites W2166969772 @default.
• W2084295556 cites W2216094174 @default.
• W2084295556 cites W2265076349 @default.
• W2084295556 cites W4233642837 @default.
• W2084295556 cites W4240813486 @default.
• W2084295556 cites W91452638 @default.
• W2084295556 doi "https://doi.org/10.1016/j.urology.2007.02.041" @default.
• W2084295556 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17572228" @default.
• W2084295556 hasPublicationYear "2007" @default.
• W2084295556 type Work @default.
• W2084295556 sameAs 2084295556 @default.
• W2084295556 citedByCount "55" @default.
• W2084295556 countsByYear W20842955562012 @default.
• W2084295556 countsByYear W20842955562013 @default.
• W2084295556 countsByYear W20842955562014 @default.
• W2084295556 countsByYear W20842955562015 @default.
• W2084295556 countsByYear W20842955562016 @default.
• W2084295556 countsByYear W20842955562017 @default.
• W2084295556 countsByYear W20842955562018 @default.
• W2084295556 countsByYear W20842955562019 @default.
• W2084295556 countsByYear W20842955562020 @default.
• W2084295556 countsByYear W20842955562021 @default.
• W2084295556 countsByYear W20842955562022 @default.
• W2084295556 crossrefType "journal-article" @default.
• W2084295556 hasAuthorship W2084295556A5014262615 @default.
• W2084295556 hasAuthorship W2084295556A5014453742 @default.
• W2084295556 hasAuthorship W2084295556A5023436882 @default.
• W2084295556 hasAuthorship W2084295556A5036761918 @default.
• W2084295556 hasAuthorship W2084295556A5047315296 @default.
• W2084295556 hasAuthorship W2084295556A5048604566 @default.
• W2084295556 hasAuthorship W2084295556A5052069729 @default.
• W2084295556 hasAuthorship W2084295556A5056602302 @default.
• W2084295556 hasAuthorship W2084295556A5081834953 @default.
• W2084295556 hasConcept C121608353 @default.
• W2084295556 hasConcept C126322002 @default.
• W2084295556 hasConcept C134018914 @default.
• W2084295556 hasConcept C2776067312 @default.
• W2084295556 hasConcept C2777164284 @default.
• W2084295556 hasConcept C2777176818 @default.
• W2084295556 hasConcept C2777944059 @default.
• W2084295556 hasConcept C2779889926 @default.
• W2084295556 hasConcept C502942594 @default.
• W2084295556 hasConcept C530470458 @default.
• W2084295556 hasConcept C54355233 @default.
• W2084295556 hasConcept C62112901 @default.
• W2084295556 hasConcept C71924100 @default.
• W2084295556 hasConcept C84606932 @default.
• W2084295556 hasConcept C86803240 @default.
• W2084295556 hasConcept C98274493 @default.
• W2084295556 hasConceptScore W2084295556C121608353 @default.
• W2084295556 hasConceptScore W2084295556C126322002 @default.
• W2084295556 hasConceptScore W2084295556C134018914 @default.
• W2084295556 hasConceptScore W2084295556C2776067312 @default.
• W2084295556 hasConceptScore W2084295556C2777164284 @default.
• W2084295556 hasConceptScore W2084295556C2777176818 @default.
• W2084295556 hasConceptScore W2084295556C2777944059 @default.
• W2084295556 hasConceptScore W2084295556C2779889926 @default.
• W2084295556 hasConceptScore W2084295556C502942594 @default.
• W2084295556 hasConceptScore W2084295556C530470458 @default.
• W2084295556 hasConceptScore W2084295556C54355233 @default.
• W2084295556 hasConceptScore W2084295556C62112901 @default.
• W2084295556 hasConceptScore W2084295556C71924100 @default.

• next